Stock Scorecard



Stock Summary for Calliditas Therapeutics AB (CALT) - $21.01 as of 3/28/2024 9:12:56 PM EST

Total Score

11 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for CALT

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for CALT

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for CALT

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for CALT

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for CALT

Palo Alto Networks Issues Weak Outlook, Joins Teladoc Health, SolarEdge Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Palo Alto Networks ( NASDAQ:PANW ) 2/21/2024 10:09:00 AM
NeoGenomics, Energy Fuels And Other Big Stocks Moving Lower On Thursday - Calliditas Therapeutics ( NASDAQ:CALT ) , Aspen Aerogels ( NYSE:ASPN ) 12/28/2023 3:53:00 PM
Micron Posts Upbeat Sales, Joins Calliditas Therapeutics And Other Big Stocks Moving Higher In Thursday's Pre-Market Session - Micron Technology ( NASDAQ:MU ) 12/21/2023 10:27:00 AM
Calliditas Therapeutics AB Sponsored ADR ( CALT ) Surges 16.1%: Is This an Indication of Further Gains? 9/22/2023 7:35:00 AM
FedEx, Splunk, FactSet Research And Other Big Stocks Moving Higher On Thursday - Calliditas Therapeutics ( NASDAQ:CALT ) , Buenaventura Mining Co ( NYSE:BVN ) 9/21/2023 2:25:00 PM
Head and Neck Squamous Cell Carcinoma Market to Witness Upsurge in Growth by 2032, Assesses DelveInsight | Key Companies in the Market - Pfizer, Merck, Eisai, AstraZeneca, Innate, Roche, GlaxoSmithKline, BeiGene, IO Biotech, Incyte 9/18/2023 9:01:00 PM
Alteryx, Iovance Biotherapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market Session 9/18/2023 11:04:00 AM
Alteryx, Iovance Biotherapeutics And Other Big Stocks Moving Higher In Monday's Pre-Market Session - Alteryx ( NYSE:AYX ) , Bitfarms ( NASDAQ:BITF ) 9/18/2023 10:34:00 AM
JNJ: Which of these 3 Pharma Stocks Should You Buy, Hold or Sell? 9/15/2023 2:05:00 PM
EXCLUSIVE: Kidney Care Revolution? How Swedish Biopharma Calliditas Aims To Tackle A Rare Disease With 'Unique, But Pretty Simple' Drug - Travere Therapeutics ( NASDAQ:TVTX ) , Calliditas Therapeutics ( NASDAQ:CALT ) , SPDR Series Trust SPDR S&P Biotech ETF ( ARCA:XBI ) 9/8/2023 12:42:00 PM

Financial Details for CALT

Company Overview

Ticker CALT
Company Name Calliditas Therapeutics AB
Country USA
Description Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing pharmaceutical products for treatments in orphan indications with an initial focus on kidney and liver diseases. The company is headquartered in Stockholm, Sweden.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 12/31/2023
Next Earnings Date 5/7/2024

Stock Price History

Last Day Price 21.01
Last Day Price Updated 3/28/2024 9:12:56 PM EST
Last Day Volume 1,163
Average Daily Volume 7,371
52-Week High 29.30
52-Week Low 15.25
Last Price to 52 Week Low 37.77%

Valuation Measures

Trailing PE N/A
Industry PE 100.07
Sector PE 60.76
5-Year Average PE -14.03
Free Cash Flow Ratio 0.58
Industry Free Cash Flow Ratio 12.70
Sector Free Cash Flow Ratio 31.04
Current Ratio Most Recent Quarter 3.13
Total Cash Per Share 36.28
Book Value Per Share Most Recent Quarter 38.53
Price to Book Ratio 18.51
Industry Price to Book Ratio 5.57
Sector Price to Book Ratio 21.66
Price to Sales Ratio Twelve Trailing Months 0.49
Industry Price to Sales Ratio Twelve Trailing Months 13.94
Sector Price to Sales Ratio Twelve Trailing Months 8.77

Share Statistics

Total Shares Outstanding 26,836,000
Market Capitalization 563,824,360
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -13.08%
Reported EPS 12 Trailing Months -1.64
Reported EPS Past Year -1.63
Reported EPS Prior Year -1.31
Net Income Twelve Trailing Months -466,184,000
Net Income Past Year -466,185,000
Net Income Prior Year -412,268,000
Quarterly Revenue Growth YOY 5.20%
5-Year Revenue Growth 59.10%

Balance Sheet

Total Cash Most Recent Quarter 973,733,000
Total Cash Past Year 973,733,000
Total Cash Prior Year 1,249,094,000
Net Cash Position Most Recent Quarter 232,989,000
Net Cash Position Past Year 260,703,000
Long Term Debt Past Year 713,030,000
Long Term Debt Prior Year 713,030,000
Total Debt Most Recent Quarter 740,744,000
Equity to Debt Ratio Past Year 0.32
Equity to Debt Ratio Most Recent Quarter 0.31
Total Stockholder Equity Past Year 334,806,000
Total Stockholder Equity Prior Year 766,263,000
Total Stockholder Equity Most Recent Quarter 334,806,000

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.09
MACD Signal -0.03
20-Day Bollinger Lower Band 16.64
20-Day Bollinger Middle Band 21.68
20-Day Bollinger Upper Band 26.72
Beta 1.39
RSI 42.48
50-Day SMA 19.63
200-Day SMA 0.00

System

Modified 3/27/2024 8:21:51 PM EST